{"name":"IMV Inc","slug":"imv","ticker":"IMV","exchange":"NASDAQ","domain":"imv-inc.com","description":"IMV Inc is a biopharmaceutical company focused on oncology and cancer immunotherapy. The company's lead product, DPX-Survivac, is an immunotherapy vaccine targeting survivin, a protein highly expressed in various cancers. IMV's pipeline also includes DPX-COVID-19, a vaccine candidate for COVID-19. IMV is a clinical-stage company with a market position in the emerging field of cancer immunotherapy.","hq":"Dartmouth, Nova Scotia, Canada","founded":0,"employees":"","ceo":"Andrew Hall","sector":"Oncology / Cancer Immunotherapy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$95M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2035-06-01","label":"DPX-Survivac patent cliff ($0.0B at risk)","drug":"DPX-Survivac","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2022-06-28","type":"regulatory","headline":"IMV Announces FDA Clearance of Investigational New Drug (IND) Application for DPX-Survivac","summary":"IMV announced that the FDA has cleared the IND application for DPX-Survivac, enabling the company to initiate a Phase 3 clinical trial in ovarian cancer.","drugName":"DPX-Survivac","sentiment":"positive"},{"date":"2021-03-15","type":"earnings","headline":"IMV Reports Fourth Quarter and Full Year 2020 Financial Results","summary":"IMV reported its financial results for the fourth quarter and full year 2020, highlighting progress in its clinical pipeline and financial position.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPVGQyRU9sYUxzVVRqQmZXVGZNNVBCQmctTkg2czBPSW5MaFZnUGdDWlZNRzY5dm5JMURvUjlSWHE4TFdKTUF6WGltWFFMQkx1a1FKN3Y5NHd6cUpkWEN0TDNzalpCdzUwQ0hBUFBOYWlRZGo5anJXckFqM3lOcUZNcnRvUTEycGMxdlUtSGt3ckREM2E2RWF3dGh2akVnd1Jtb0lzU1VuQjlpTklWelhfR0RiVkxwVHB6cWhRRW0xMmtTd01RUlZUQlRkSlk0eTROV0VuMFhBVkxuZXVLdDU3TzV3Y3pUT21BRlR6WUFKWTV3V2c?oc=5","date":"2025-12-12","type":"regulatory","source":"Citeline News & Insights","summary":"Teva’s Estradiol Approved As The First Generic To Imvexxy By The FDA - Citeline News & Insights","headline":"Teva’s Estradiol Approved As The First Generic To Imvexxy By The FDA - Citeline News & Insights","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE93aUlIU0VVbXFzZFFJMmhZcndUX1lTdTN6ZXlSejZVS0I1OFFPSkZaVk52X25SVnlReVc1UFlpLUpUZXBUYXdSdjVEaTkwZFIyOEdZ?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"DFFN Stock Price, News & Analysis - Stock Titan","headline":"DFFN Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQVDhOY00yeW1CSDdQSkZlRW9DUXV2SmlSUFlGT0hINXlpVlFQQUlCeFpubGdia25Sb1NXODB6djJ5ZEhCZDh1LWhKZGh0ekc3Z3QxZzdKSWNKUmpCS3pNVTNHYUxhazlqNUhCRmZsQV9WNXBKc0xUZ2VwdW0wUnBlM3NVa0tsWE5IYzJzZEtacHFBTnRX?oc=5","date":"2025-04-07","type":"pipeline","source":"3tres3.com","summary":"Change at the top at IMV Technologies Group: Oliver Kohlhaas succeeds Alain de Lambilly as CEO - 3tres3.com","headline":"Change at the top at IMV Technologies Group: Oliver Kohlhaas succeeds Alain de Lambilly as CEO - 3tres3.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1uUzRobVlnRG9Jc0Jzc1V6eTRaSllzN0U0UzQ2MTVQamVLektVM0JqM2UzU1ozTWNOdTg1aEF4a2RBblFRVmlGci1DZkVscjBHTkpFdk51UUhwOXpoeTc0?oc=5","date":"2025-03-22","type":"pipeline","source":"nature.com","summary":"A bispecific anti-MUC16/anti-death receptor 5 antibody achieves effective and tumor-selective death receptor 5-mediated tumor regression - nature.com","headline":"A bispecific anti-MUC16/anti-death receptor 5 antibody achieves effective and tumor-selective death receptor 5-mediated ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxOam9KMmthVDZ5NEdrcEpralZBcDdBOHlWX3lwYmI0MW9XTDVoeGdLdVBSbDYzdXcwR3BOaG5VcFVpdlViSllxNnU4T2swbFVrTHpUNmFsX09aazdKNUpyNzVTeGZKUXpIeGRDN3AzRVVRZDF3eU51TWg2dVFDV3RZOTc5V0J0X3B5SFNJU1A0aG00NmpUQzYtd0JHZ0gzRWlqWEZMNFMwTVVjQmdVamxrc29scGFuNmhic1JrZHl0ektVOEthVFlxbUFJN0lINmc4V2FCYzFBLWZsMnJuc1czZWJNYk82MC1sVHhRN0gxMXlPUjBObTc2MktzZE4xVGY5RmpOSlA0ZE5yN1hFZ3BRUUtCa3U2YU44SEhwS21vb1M3alMwOExJX3lBWUpxaUk?oc=5","date":"2024-02-21","type":"pipeline","source":"PR Newswire","summary":"BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC. - PR Newswire","headline":"BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL ST","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPUWxsR0RYUWp1NEhSeTlvQzNLZXM0cm1OTFdwZXR5VnhNS2k1MWxoT2owR0tBZF9pQlJPQzFrTEM0dTNqMVlvdTlYbVJTT3dIdWloNGJMM0lKV3FLYW4wRVVQNmVUdHhVTndWTDVKVHR2al9iRWc5TmNVV3FnTWRLYlFsZw?oc=5","date":"2024-02-15","type":"deal","source":"PharmTech.com","summary":"BioVaxys Acquires Full Portfolio of Former IMV - PharmTech.com","headline":"BioVaxys Acquires Full Portfolio of Former IMV","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNSlJMSkVaMEZQSzMxQUdGOVBHTVdQNHdtbUFqRFB2WTdDb0JQemdwOU1iTVVXcVZxTEZCUGR5YlRIcGtzSFUyLWcwOUJsaTBaYmdNNnk3S3Y4TjNiem5mT1Nkem8wZmpNcUczZm1WRWdKMjdOdXFwNEc5dllxczNpSEpTVmJmVkgzOENZMGIxQjRTVzZZTHdTNHJxc1I0S1lJTkhBa3dtUTdvMkotT1NvVXhzVXk?oc=5","date":"2024-02-13","type":"pipeline","source":"Pharmaceutical Technology","summary":"BioVaxys snatches up ‘bankrupt’ IMV’s preclinical and clinical assets - Pharmaceutical Technology","headline":"BioVaxys snatches up ‘bankrupt’ IMV’s preclinical and clinical assets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNT0p1Z21fVlpqdmJxM1dLc0dydnF5YnpOVWowZmdMOGlTTlhHNWRwaVhGWHo3LVZiM3ktNUtHSV9wY0xaZkR0d01OREtGRjVRa2lrSy1HbVR5WFlSTUE4ejhxSVZSNWZ6ODQ0ZWtQX3RaWlNZTkZPUDNycW1LRTgwWnJBV1EwczRmNDRkTUxpNy1RdnRIbGNhb25IU1NVd3FTbjNSVHUtVl82T1BxbmJqaXYwdlhLUWNnZ05aSDh2MUE?oc=5","date":"2024-02-12","type":"deal","source":"Contract Pharma","summary":"BioVaxys Acquires IP, Immunotherapeutics Platform Technology & Assets of IMV Inc. - Contract Pharma","headline":"BioVaxys Acquires IP, Immunotherapeutics Platform Technology & Assets of IMV Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxPSGVJZ1ROU1ZyMVprY1VlYUtxVXRiM3l0aXFXSEs2ZzFHUW9XWjNEWVI3X0xRbE1UeHU4TVVZbGx0TjVxc1diNjNCNEVkR3FZNlRzYlZjQ0tDVXVmWkxDRy01anN1YUVTbk9ISG5UXy1xdW9mVVgxSmJJcW42VzFvc25vOTZVWl9fY0VBckFFYV91MXREOGQ2cWlqaHVJQkdxRkZ3S1huREwxS3ZCZFlXVUU5U09XV3JOMmRWRDNHOVMtU0ZuUDJsbXA0UVZIeHU5RFlqWE4zZC1SUWhKQnI0SzdPRjhmVUlUYnFwclZDQ3Y5SlpIQXVfSk5mLUlHSzNCbjFLN2RYakx2RlN4UHUtcHZvVC0?oc=5","date":"2024-02-12","type":"deal","source":"PR Newswire","summary":"BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc. - PR Newswire","headline":"BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Fo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxOME9FUGQxbkRMTW1zTjBqaE04bVBYRFl6cERaWnRSVmg0OGJjY29RNkRsQXFjTmdON2VNd1FtYmZhOHJVcnhVSEpXYVJLaVRKWlFWS3VmSkwzM2hidW1JdWdvSUY2UHh1WWJGZWNlajlCNnM3TlJxbTlmNjFXVHE1dHFUSjliUGdiakNsR0pzaS1Bei1nWUFMSlc5UnlfNEgyODJxN25OLU1YcEQ4OUsydnJGZ0pyVDFnRngyTDNPMDNJOTFhanU4UHNFUVdWdWl6eUo5b2VEU3ZGdFhBcnJXeWd3VTVyUVJMeXJMWTI2U2Rrc2gwSEZvcFVPbjdSYk5C?oc=5","date":"2023-03-16","type":"earnings","source":"Business Wire","summary":"IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results - Business Wire","headline":"IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNejRJTWI4U2VzYzM0SmRoVURqeS1EUFZqdnJHWjQwSUhlbEVkT2h4YnFSUGF0cEdGeHIwaEFVZDZ3dzh5bVpqdER0UnJ5aGExSlpUT1hhNXY1VURUemN4eWRsSFhRVzZPLURVV3dqdDItdUd6bzNhd0ZkeUJvX2tYanJhOGhPOGUyeDhGeE9lVkFHRDNGSFFSRXdsM0hLUTk0aW1hVA?oc=5","date":"2021-02-17","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Q&A: Why IMV’s DPX-Survivac shows promise in treating ovarian cancer - drugdiscoverytrends.com","headline":"Q&A: Why IMV’s DPX-Survivac shows promise in treating ovarian cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPOGg0SmdPRlNtSHdldXJtOWpGTUR5ZnBZV3YtS2ViTzFUdWpDb2lTa2dMSWdYbGFfR01vTmFsdGdWYUtFcnhtUnJBczFaU21FM3pMOHc4aW1qQXN5TFlwNU54Q2lPbjN0amFIbWR5VWd5QnJ4VWNqN2lCRDR1MUlDUXBVdlRTQTEtdlY4ZVJXZkd5YnJCV3Z6dU9GRndndjJ3WjJvREU1Y0szdXd3S3VEQ1lWOHFsUQ?oc=5","date":"2020-02-25","type":"trial","source":"Fierce Biotech","summary":"IMV's T-cell programming treatment keeps ovarian cancer at bay in midphase study - Fierce Biotech","headline":"IMV's T-cell programming treatment keeps ovarian cancer at bay in midphase study","sentiment":"neutral"}],"patents":[{"drugName":"DPX-Survivac","drugSlug":"survivin","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BioNTech","Moderna Therapeutics","Incyte Corporation"],"therapeuticFocus":["Oncology","Cancer Immunotherapy"],"financials":null,"yahoo":null}